Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q86SF2
UPID:
GALT7_HUMAN
Alternative names:
Polypeptide GalNAc transferase 7; Protein-UDP acetylgalactosaminyltransferase 7; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 7
Alternative UPACC:
Q86SF2; B3KQU3; Q7Z5W7; Q9UJ28
Background:
N-acetylgalactosaminyltransferase 7, known alternatively as Polypeptide GalNAc transferase 7, Protein-UDP acetylgalactosaminyltransferase 7, or UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 7, plays a crucial role in O-linked oligosaccharide biosynthesis. This enzyme uniquely catalyzes the addition of N-acetyl-D-galactosamine residues to glycosylated peptides, requiring a pre-existing GalNAc on a peptide for further GalNAc additions, unlike its family counterparts.
Therapeutic significance:
Understanding the role of N-acetylgalactosaminyltransferase 7 could open doors to potential therapeutic strategies.